Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133368 | 1.00 | POLB (0.41) | POLBMGAMALDH1A1P4HA1P4HTM | |
| SCHEMBL27138497 | 0.87 | POLB (0.41) | POLBMGAMALDH1A1P4HA1P4HTM | |
| SCHEMBL30711991 | 0.86 | NNMT (0.48) | FBP1NNMTPSMD14 | |
| SCHEMBL30634351 | 0.85 | POLB (0.40) | POLBMGAMALDH1A1P4HA1P4HTM | |
| SCHEMBL16415942 | 0.85 | POLB (0.40) | POLBMGAMALDH1A1P4HA1P4HTM | |
| SCHEMBL26633281 | 0.77 | FBP1 (0.36) | FBP1KDM4EHSD17B10 | |
| SCHEMBL29377632 | 0.76 | ALDH1A1 (0.52) | POLBMGAMALDH1A1P4HA1P4HTM | |
| SCHEMBL3805068 | 0.76 | ALDH1A1 (0.47) | MGAMALDH1A1P4HA1P4HTMMIF | |
| SCHEMBL2729684 | 0.76 | ALDH1A1 (0.52) | POLBMGAMALDH1A1P4HA1P4HTM | |
| Hydrochloric Acid SCHEMBL846544 | 0.75 | ALDH1A1 (0.50) | POLBMGAMALDH1A1P4HA1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3856178-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| EP-2474543-B1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-9249135-B2 | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433938-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | POLB 2269/4885MGAM 163/4885ALDH1A1 312/4885 |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | POLB 4565/4885MGAM 3661/4885ALDH1A1 122/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | POLB 1982/4885MGAM 863/4885ALDH1A1 587/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | POLB 2269/4885MGAM 163/4885ALDH1A1 312/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | POLB 2269/4885MGAM 163/4885ALDH1A1 312/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | POLB 4607/4885MGAM 2952/4885ALDH1A1 32/4885 |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | POLB 2019/4885MGAM 2065/4885ALDH1A1 216/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | POLB 4607/4885MGAM 2952/4885ALDH1A1 32/4885 |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | POLB 4607/4885MGAM 2952/4885ALDH1A1 32/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | POLB 2269/4885MGAM 163/4885ALDH1A1 312/4885 |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | POLB 2019/4885MGAM 2065/4885ALDH1A1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.